I think we need to distinguish between potential deals and potential revenue over the coming 12 months.
Deals or perhaps arrangements should be announced, however they may not result in revenue.
The share price should get a push on the deals being announced but if the revenue doesn't come then we will find ourselves short of cash again and forced to go back for another CR.
At this stage the company has said that the pilot plant will be used for internal testing purposes and supply to third parties for testing, so I don't see much revenue being generated from it until it production goes into an actual battery under mass production and for actual sale. So at this stage pilot plant sales should be largely discounted until we hear otherwise. Hopefully we will at some stage (b4 year end) go into a battery say in the consumer electronics area but that's not a given
I think we will need the first round of options - and I'd prefer to have those as potential funding rather than have to go back to the market.
If the options are struck down by shareholders that may also make any future CR harder to place going forward and mean an even bigger discount or even more generous freebies thrown in to attract the Sophisticated Investors as the current shareholders have only contributed less than $2m over the last two raises. I'm opposed to the 2nd round of options as we hopefully shouldn't need them by that stage but alas they both go hand in hand.
Below is a rather crude cashflow based on where we are now assuming nothing too much happens in the way of revenue.
It assumes lower cash outflow of $2.6m a quarter with no litigation costs or plant build - 250k a month inflow for the current grant being drawn down and 125k growing to 450k in quarterly sales (just note 1000 litres of Anteo sales would bring in 400k a quarter - and we have only sold 150 litres over the last 6 months).
Everybody will have a different opinion on this - but this I did to get an idea for my own purposes of how things may track.
One thing to consider is the 4C requires us to have 2 quarters of cash left or an explanation on how we will continue to fund the business if we don't. I see us potentially struggling with this by the September quarter ... although we should in fact have enough cash to last to March 2025 with the R&D credit - so I think we will need further funding and the options as an explanation if required for the 4C
Mar24 Cash Bal 1618 1 Jun Qtr Outflow -2600 2 Placement 5000 3 SPP 1400 4 Grant usage 250 5 Sales 125 6 Jun24 Cash Bal 5793 7 Sep Qtr Outflow -2600 8 Grant usage 250 9 Sales 125 10 Sep24 Cash Bal 3568 11 Dec Qtr Outflow -2600 12 Grant usage 250 13 Sales 150 14 R&D 3000 15 Dec24 Cash Bal 4368 16 Mar Qtr Outflow -3250 17 Grant usage 250 18 Sales 450 19 Mar25 Cash Bal 1818 20 Jun Qtr Outflow -3100 21 Grant usage 250 22 Sales 450 23 Jun25 Cash Bal -582
- Forums
- ASX - By Stock
- ADO
- why ADO is a multi multi bagger
why ADO is a multi multi bagger, page-432
-
- There are more pages in this discussion • 2,563 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ADO (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.2¢ |
Change
-0.005(18.5%) |
Mkt cap ! $53.53M |
Open | High | Low | Value | Volume |
2.1¢ | 2.2¢ | 2.1¢ | $131.5K | 6.186M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 3079013 | 2.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.2¢ | 588569 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 3038323 | 0.021 |
21 | 4661032 | 0.020 |
8 | 3328823 | 0.019 |
14 | 3352391 | 0.018 |
5 | 2369748 | 0.017 |
Price($) | Vol. | No. |
---|---|---|
0.022 | 438789 | 4 |
0.023 | 625000 | 3 |
0.024 | 200000 | 1 |
0.025 | 40000 | 1 |
0.026 | 76000 | 2 |
Last trade - 14.23pm 13/11/2024 (20 minute delay) ? |
Featured News
ADO (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online